ASTERDM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | ASTERDM | Market Cap | 41,940 Cr. | Current Price | 809 ₹ | High / Low | 848 ₹ |
| Stock P/E | 128 | Book Value | 84.3 ₹ | Dividend Yield | 0.62 % | ROCE | 10.8 % |
| ROE | 8.94 % | Face Value | 10.0 ₹ | DMA 50 | 739 ₹ | DMA 200 | 661 ₹ |
| Chg in FII Hold | -1.28 % | Chg in DII Hold | 1.45 % | PAT Qtr | 85.3 Cr. | PAT Prev Qtr | 58.9 Cr. |
| RSI | 63.9 | MACD | 18.0 | Volume | 8,51,295 | Avg Vol 1Wk | 5,69,725 |
| Low price | 519 ₹ | High price | 848 ₹ | PEG Ratio | 5.41 | Debt to equity | 0.31 |
| 52w Index | 88.2 % | Qtr Profit Var | 3.43 % | EPS | 5.17 ₹ | Industry PE | 46.3 |
📊 Aster DM Healthcare shows moderate fundamentals but trades at very high valuations. With ROE at 8.94% and ROCE at 10.8%, capital efficiency is relatively weak compared to peers. The P/E of 128 vs. industry PE of 46.3 highlights significant overvaluation. Dividend yield of 0.62% is modest, while PEG ratio of 5.41 suggests growth is not keeping pace with valuation. Debt-to-equity at 0.31 is manageable, and quarterly PAT growth shows some improvement, but overall metrics indicate caution for long-term investors.
💰 Ideal Entry Zone: 680 ₹ – 740 ₹, aligning with support levels near DMA 50 (739 ₹) and DMA 200 (661 ₹). This range offers a safer entry considering stretched valuations.
📈 Exit Strategy / Holding Period: For existing holders, a medium-term horizon (2–3 years) is advisable. Consider partial profit booking near 830–850 ₹ resistance levels. Exit fully if ROE/ROCE fail to improve or if valuations remain unsustainably high. Otherwise, hold cautiously with close monitoring of earnings growth.
🌟 Positive
- Quarterly PAT growth from 58.9 Cr. to 85.3 Cr. (+3.43%).
- EPS of 5.17 ₹ supports profitability.
- Debt-to-equity ratio at 0.31 is manageable.
- Strong [DII holding](ca://s?q=DII_Holding) increase (+1.45%) reflects domestic support.
⚠️ Limitation
- High [P/E ratio](ca://s?q=Explain_PE_ratio) of 128 vs. industry average of 46.3.
- Weak [ROE](ca://s?q=Explain_ROE) at 8.94% and [ROCE](ca://s?q=Explain_ROCE) at 10.8%.
- Low [dividend yield](ca://s?q=Dividend_yield) of 0.62% offers limited income stability.
- PEG ratio of 5.41 indicates growth not keeping pace with valuation.
📉 Company Negative News
- Decline in [FII holding](ca://s?q=FII_Holding) (-1.28%) shows reduced foreign investor confidence.
📈 Company Positive News
- Quarterly PAT growth highlights operational improvement.
- Increase in [DII holding](ca://s?q=DII_Holding) reflects domestic institutional support.
🏭 Industry
- Industry PE at 46.3 vs. Aster DM PE at 128 highlights significant overvaluation.
- Healthcare sector demand expected to remain resilient with rising medical needs and infrastructure expansion.
✅ Conclusion
Aster DM Healthcare is not an ideal candidate for long-term investment at current valuations due to weak ROE/ROCE and high P/E. Ideal entry is 680–740 ₹ for risk-adjusted positioning. Existing holders should adopt a cautious 2–3 year horizon, with profit booking near 830–850 ₹ resistance levels or exit if fundamentals fail to improve.